Download PDF
Thromb Haemost 1997; 78(01): 689-692
DOI: 10.1055/s-0038-1657613
Prevention and treatment of deep vein thrombosis
Schattauer GmbH Stuttgart

Low Molecular Weight Heparin for the Out-of-Hospital Treatment of Venous Thrombosis: Rationale and Clinical Results

Jack Hirsh
Hamilton Civic Hospitals Research Centre, Hamilton, Ontario, Canada
,
Mark Crowther
Hamilton Civic Hospitals Research Centre, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
30 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Hull R, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, McLoughlin D, Armstrong P. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. New Engl J Med 1979; 301: 855-858
    CrossrefPubMedGoogle Scholar
  • 2 Hirsh J. The optimal duration of anticoagulant therapy for venous thrombosis. New Engl J Med 1995; 332: 1710-1711
    CrossrefPubMedGoogle Scholar
  • 3 Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, Hirsh J, Martin GJ, Green D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. New Engl J Med 1990; 322: 1260-1264
    CrossrefPubMedGoogle Scholar
  • 4 Hirsh J. Heparin. New Engl J Med 1991; 324: 1565-1574
    CrossrefPubMedGoogle Scholar
  • 5 Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WHR, Rosenbloom D, Sackett DL, Anderson C, Harrison L, Gent M. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. New Engl J Med 1986; 315: 1109-1114
    CrossrefPubMedGoogle Scholar
  • 6 Hirsh J, Dalen JE, Deykin D, Poller L, Bussey HI. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995; 108 (04) 231s-246s
    CrossrefPubMedGoogle Scholar
  • 7 Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, Turpie AGG, McLoughlin D, Dodd P, Thomas M, Raskob G. Ockelford P Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. New Engl J Med 1982; 307: 1676-1681
    CrossrefPubMedGoogle Scholar
  • 8 Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med 1989; 87: 153-159
    CrossrefPubMedGoogle Scholar
  • 9 Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-152
    CrossrefPubMedGoogle Scholar
  • 10 Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, Van derMeer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, Bossuyt PMM, DeHaes H, Van DenBelt AGM, Sagnard L, D’Azemar P, Buller HR. for the TASMAN study group. Treatment of patients with proximal-vein thrombosis with intravenous unfractionated heparin in hospital compared with subcutaneous low-molecular-weight heparin out of hospital or with early discharge. New Engl J Med 1996; 334: 682-687
    CrossrefPubMedGoogle Scholar
  • 11 Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg JS, Turpie AG, Demers C, Kovacs M, Geerts W, Kassis J, Desjardins L, Cusson J, Cruickshank M, Powers P, Brien W, Haley S, Willan A. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New Engl J Med 1996; 334: 677-681
    CrossrefPubMedGoogle Scholar
  • 12 Monreal M, Lafoz E, Olive A, del RioL, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71: 07-11
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla F, Poli TT, Tagliaferri A, Dettori AG. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994; 72: 191-197
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Kakkar VV. Dalteparin prevention of recurrent DVT-a study versus warfarin. Haemostasis 1994; 24 (Suppl. 01) s45
    PubMedGoogle Scholar
  • 15 Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 01-17
    PubMedGoogle Scholar
  • 16 Frydman AM, Bara L, Le RouxY, Woler M, Chauliac F, Samama MM. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharm 1988; 28: 609-618
    CrossrefPubMedGoogle Scholar
  • 17 Briant L, Caranobe C, Saivin S, Sie P, Bayrou B, Houin G, Boneu B. Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit. Thromb Haemost 1989; 61: 348-353
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Bratt G, Tornebohm E, Widlund L, Lockner D. Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986; 42: 613-620
    CrossrefPubMedGoogle Scholar
  • 19 Matzsch T, Bergqvist D, Hedner U, Ostergaard P. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 1987; 57: 97-101
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Handeland GF, Abildgaard U, Holm HA, Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharm 1990; 39: 107-112
    CrossrefPubMedGoogle Scholar
  • 21 Boneu B, Buchanan MR, Caranobe C, Gabaig AM, Dupouy D, Sie P, Hirsh J. The disappearance of a low molecular weight heparin fraction (CY 216) differs from standard heparin in rabbits. Thromb Res 1987; 46: 845-853
    CrossrefPubMedGoogle Scholar
  • 22 Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994; 71: 300-304
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Young E, Cosmi B, Weitz J, Hirsh J. Comparison of the nonspecific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. Thromb and Haemost 1993; 70: 625-630
    PubMedGoogle Scholar
  • 24 Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent MK, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. New Engl J Med 1995; 332: 1330-1335
    CrossrefPubMedGoogle Scholar
  • 25 Murray WJ, Lindo VS, Kakkar VV, Melissari E. Long-term administration of heparin and heparin fractions and osteoporosis in experimental animals. Blood Coag Fibrin 1995; 06: 113-118
    CrossrefPubMedGoogle Scholar
  • 26 Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-1245
    PubMedGoogle Scholar
  • 27 Esquivel CO, Bergqvist D, Bjorck CG, Nilsson B. Comparison between commercial heparin, low molecular weight heparin and pentosan polysulfate on hemostasis and platelets in vivo. Thromb Res 1982; 28: 389-399
    CrossrefPubMedGoogle Scholar
  • 28 Cade JF, Buchanan MR, Boneu B, Ockelford P, Cater CJ, Cerskus ALH, Hirsh J. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res 1984; 35: 613-625
    CrossrefPubMedGoogle Scholar
  • 29 Holmer E, Mattsson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 1982; 25: 475-485
    CrossrefPubMedGoogle Scholar
  • 30 Andriuoli G, Mastacchi R, Barbanti M, Sarret M. Comparison of the antithrombotic and haemorrhagic effects of heparin and a new low molecular weight heparin in rats. Haemostasis 1985; 15: 324-330
    PubMedGoogle Scholar
  • 31 Bergqvist D, Nilsson B, Hedner U, Pedersen PC, Ostergaard PB. The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis. Thromb Res 1985; 38: 589-601
    CrossrefPubMedGoogle Scholar
  • 32 Lindmarker P, Holmstrom M. Use of low molecular weight heparin (dalteparin), once, for the treatment of deep vein thrombosis is. A feasibility and health economic study in an outpatient setting. J Int Med 1996; 240: 395-401
    CrossrefPubMedGoogle Scholar
  • 33 Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Int Med 1995; 155: 601-607
    CrossrefPubMedGoogle Scholar